---
document_datetime: 2024-11-04 13:31:05
document_pages: 32
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aflunov-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aflunov-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 16.3433428
conversion_datetime: 2025-12-26 18:30:43.013201
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aflunov

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------|
| II/0086              | Extension of indication to include treatment of individuals 6 months of age and older for AFLUNOV, based on final results from study V87_30. This is a Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content | 19/09/2024                          | 21/10/2024                                  | SmPC, Labelling and PL           | Please refer to Scientific Discussion Aflunov- EMEA/H/C/002094/II/0086 |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | in a Monovalent H5N1 Pandemic Influenza Vaccine in Healthy Pediatric Subjects 6 Months to < 9 Years of Age. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 5.4 of the RMP has also been approved. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes to the product information including updating the SmPC in line with EMA guidance regarding sodium and potassium content. The variation leads to amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10008 /202310 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16/05/2024 | n/a | PRAC Recommendation - maintenance |
| II/0084/G           | This was an application for a group of variations. B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 20/07/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| duplication of line) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect   |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10008 /202210 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12/05/2023 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

|           | vaccine (H5N1) (surface antigen, inactivated, adjuvanted)                                                                                                                                                                                                                                                                                                              |            |            |                                  |                                                                                                                                                                                                                                                                         |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0082   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                       | 17/01/2023 | n/a        |                                  |                                                                                                                                                                                                                                                                         |
| IB/0080   | To update sections 4.4, 4.5 4.8 and 6.6 of the to increase clarity and harmonisation with the text approved in the Foclivia SmPC and with Seqirus seasonal vaccines (Fluad Tetra and Flucelvax Tetra). The labelling and package leaflet have been amended accordingly. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 30/09/2022 | 27/02/2023 | SmPC, Annex II, Labelling and PL | To update sections 4.4, 4.5 4.8 and 6.6 of the to increase clarity and harmonisation with the text approved in the Foclivia SmPC and with Seqirus seasonal vaccines (Fluad Tetra and Flucelvax Tetra). The labelling and package leaflet have been amended accordingly. |
| WS/2341   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                               | 29/09/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                         |
| WS/2248/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or                                                                                                                                                                 | 10/06/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |     |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10008 /202110 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)                                                                                                                                                                                                                                                                                                                                                                               | 10/06/2022 | n/a | PRAC Recommendation - maintenance |
| WS/2236/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                       | 02/06/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| WS/2151   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the RMP (part I, II, III, IV, V and VI) for AFLUNOV and FOCLIVIA in order to align the list of safety concerns for the products. The modules 'Epidemiology of the indication and target population' and 'Identified and potential risks' and the section of missing information are updated. Some potential risks have been reclassified following the definition as per GVP Module V rev.2. RMP version 4.0 was approved with this variation. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   | 05/05/2022   | n/a        |                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|
| IA/0079   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 20/04/2022   | n/a        |                       |
| WS/2226/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.c - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 31/03/2022   | 27/02/2023 | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/2178/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for | 09/12/2021 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                    |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/2152             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                       | 18/11/2021 | n/a |                                   |
| WS/2167             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                             | 11/11/2021 | n/a |                                   |
| IA/0070             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                        | 04/08/2021 | n/a |                                   |
| WS/1985             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 01/07/2021 | n/a |                                   |
| PSUSA/10008 /202010 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza                                                                                                                                    | 10/06/2021 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

|           | (H5N1) (surface antigen, inactivated,                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                 | vaccine adjuvanted)   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------|
| IA/0069   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/02/2021 | 24/03/2022 | Annex II and PL |                       |
| WS/1958/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 10/12/2020 | n/a        |                 | procedure             |
| WS/1982   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                 | 03/12/2020 | n/a        |                 |                       |
| IA/0066/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or                                                                                                                                                                                                                                                                         | 06/11/2020 | n/a        |                 |                       |

<div style=\"page-break-after: always\"></div>

|           | used in the manufacture of the AS or manufacturer of a novel excipient - Change in the specification parameters limits of an AS, starting material/intermediate/reagent - Deletion of a non- specification parameter (e.g. deletion of obsolete parameter)                                                                                                                                                                                                 |            |     | intermediate B.I.b.1.d and/or significant an   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------|
| IA/0064/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)       | 20/10/2020 | n/a |                                                |
| WS/1796/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of Member State - Excipient/AS starting material | 03/09/2020 | n/a | a                                              |

<div style=\"page-break-after: always\"></div>

| WS/1860   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/07/2020   | n/a   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| WS/1823/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 02/07/2020   | n/a   |
| IA/0062   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 29/05/2020   | n/a   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10008 /201910   | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza                                                                                      | 14/05/2020   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IB/0058               | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                           | 27/02/2020   | n/a        |                        |                                     |
| IB/0056               | B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                 | 17/01/2020   | n/a        |                        |                                     |
| IB/0055               | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                           | 09/12/2019   | n/a        |                        |                                     |
| IAIN/0054             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 22/10/2019   | 25/06/2020 | Annex II and PL        |                                     |
| IAIN/0053             | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                             | 06/09/2019   | 25/06/2020 | SmPC, Labelling and PL |                                     |
| WS/1628               | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                          | 25/07/2019   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1600/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal | 27/06/2019 | 25/06/2020 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0044/G | This was an application for a group of variations. Update of sections 2, 4.1, 4.4, 4.5, 4.6, 4.8 and 5.1 of the SmPC in order to update the immunogenicity and safety data based on final results from two phase III stratified, randomized, controlled, observer-blind, multicenter studies in adult and elderly subjects with comorbidity (study V87_25) or immunosuppressive conditions (study V87_26),                                                                                                                                                                                                                           | 27/06/2019 | 25/06/2020 | SmPC, Annex II, Labelling and PL | The MAH submitted final results from two studies included in the RMP that investigated immunogenicity and safety of two doses of Aflunov; 7.5 Âµg HA/dose) in adults and elderly (>61 years old) subjects with underlying medical conditions (study V87_25) or immunosuppressive conditions (study V87_26) compared to healthy individuals. The vaccine was immunogenic and safe in the population studied; however immune responses were low in elderly, immunocompromised and subjects with co-morbidities |

<div style=\"page-break-after: always\"></div>

|                     | listed as post approval commitments in the RMP. Further data were also collected in the healthy adult and elderly populations used as comparison. The Package Leaflet and Labelling are updated accordingly. The updated RMP version 3.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the PI in light with the CHMP guideline on influenza vaccines and the SmPC guideline, and to make minor editorial corrections. The MAH took the opportunity to include editorial changes in Annex II to remove the manufacturers of the biological active substance GSK Vaccines, S.r.l. Via Fiorentina 1, 53100 Sienna, Italy and GSK Vaccines S.r.l. Bellaria - Rosia, 53018 Sovicille (Siena) Italy, following the outcome of procedure WS/xxxx/1145/G. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |     | compared to the immunogenicity profile in healthy adults. Antibody responses in patients with endogenous or iatrogenic immunosuppression may be insufficient to provide protection. In addition, some degree of cross- reactive immunity has been observed against H5N1 viruses of clades different to that of the vaccine strain. However, the degree of protection that may be elicited to H5N1 strains of other clades is unknown. Although the data suggest that the safety profile is similar in immunocompromised subject and subject with comorbidities to that observed in healthy subjects, some immunosuppressive conditions (tumors and transplant recipients) or comorbidities (especially vascular diseases and renal impairment) are scarcely represented. Consequently, such conditions are still considered missing information in the RMP. Therefore the use of the vaccine in subjects with such conditions should be strictly monitored and reported through PSUR.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10008 /201810 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 16/05/2019 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| IAIN/0052   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                 | 10/05/2019   | n/a   |                       |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------|
| WS/1562/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition                                                                                                                                      | 02/05/2019   | n/a   | of a new in-process   |
| IB/0050/G   | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where takes place | 25/04/2019   | n/a   | batch control/testing |
| WS/1530/G   | This was an application for a group of variations following a worksharing procedure according to                                                                                                                                                                                                                                                                                                                                                                                                                   | 28/03/2019   | n/a   |                       |

<div style=\"page-break-after: always\"></div>

|         | Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging   |            |     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/1538 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/12/2018 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                   |            |     |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/1368/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure | 21/06/2018 | n/a |                                   |
| PSUSA/10008 /201710 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)                                                                                                                                                                                                                                                             | 17/05/2018 | n/a | PRAC Recommendation - maintenance |
| WS/1311/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                | 08/03/2018 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method   |            |     | B.I.a.2.c - Changes   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|
| WS/1323 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                           | 01/02/2018 | n/a |                       |
| WS/1214 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                       | 19/10/2017 | n/a |                       |
| WS/1165 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of                                                                                                                                                                                                                                                              | 20/07/2017 | n/a |                       |

<div style=\"page-break-after: always\"></div>

|           | AS - Minor change in the manufacturing process the AS                                                                                                                                                                                                                                                                                                                                                                                   |            |     | the of   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|
| WS/1143   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS                                                                                                               | 20/07/2017 | n/a |          |
| WS/1170   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                | 06/07/2017 | n/a |          |
| WS/1145/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal | 15/06/2017 | n/a |          |

<div style=\"page-break-after: always\"></div>

|                     | product and is not related to a protocol B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |                        |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-----------------------------------|
| IA/0038/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an | 01/06/2017 | n/a |                        |                                   |
| IA/0037             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                          | 19/05/2017 |     | SmPC, Labelling and PL |                                   |
| II/0032             | B.II.b.3.e - Change in the manufacturing process of the finished or intermediate product - Introduction or increase in the overage that is used for the AS                                                                                                                                                                                                                                                                                                                                                                              | 18/05/2017 | n/a |                        |                                   |
| PSUSA/10008 /201610 | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)                                                                                                                                                                                                                                                                                                                             | 05/05/2017 | n/a |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0026/G   | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where control/testing takes place                                                                                                                                                                                                                                                                               | 15/12/2016   | n/a   | batch   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------|
| IAIN/0030/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name | 22/08/2016   | n/a   |         |

<div style=\"page-break-after: always\"></div>

|             | and/or address of a manufacturer/importer responsible for batch release A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                       |            |            |                                  |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0029     | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/08/2016 | n/a        |                                  |
| IAIN/0028/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites | 13/05/2016 | 16/08/2016 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| PSUSA/10008 /201510   | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)                                                                                                                                                                                                | 13/05/2016   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                             |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0025/G             | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits | 23/09/2015   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                               |
| IAIN/0024             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                     | 12/08/2015   | 16/08/2016 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                               |
| R/0021                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                    | 21/05/2015   | 17/07/2015 | SmPC, Annex II, Labelling and PL | Based on the review of available information, the CHMP is of the opinion that the quality, safety and efficacy of AFLUNOV continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable. The CHMP recommends that the renewal be granted with unlimited validity. |
| PSUSA/10008           | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                              | 21/05/2015   | 17/07/2015 |                                  | Please refer to Aflunov PSUSA/00010008/201410 EPAR:                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| /201410   | pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)                                                                                                                                                                                                                                                                                      |            |            |                        | Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------|
| T/0023    | Marketing Authorisation Transfer from Novartis Vaccines and Diagnostics S.r.l to Novartis Vaccines Influenza S.r.l Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                             | 05/05/2015 | 27/05/2015 | SmPC, Labelling and PL |                                                                                                             |
| IAIN/0022 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                    | 30/04/2015 | n/a        |                        |                                                                                                             |
| IB/0020/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 22/04/2015 | n/a        |                        |                                                                                                             |
| II/0018/G | This was an application for a group of variations. B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for                                                                                                                                                                                                                                                                                           | 26/03/2015 | n/a        |                        |                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | sterile and non-frozen biological/immunological ASs B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.II.h.1.b.1 - Update to the Adventitious Agents Safety Evaluation information - Replacement of obsolete studies related to manufacturing steps and adventitious agents already reported in the dossier - with modifications of risk assessment B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product   |            |     |                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0017/G | This was an application for a group of variations. B.I.c.1.z - Change in immediate packaging of the AS - Other variation B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                        | 01/09/2014 | n/a |                                   |
| PSUV/0014 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 08/05/2014 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IG/0426   | - Introduction of or changes to a summary of system - Changes in QPPV contact details) and/or changes in the location                                                                                                                                                                                                                                                                                                   | 11/04/2014   | n/a        |                                  | C.I.8.a Pharmacovigilance (including PSMF   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------------------------------------------|
| IA/0015/G | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with method | 28/03/2014   | n/a        |                                  | its corresponding test                      |
| IB/0013   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                          | 30/10/2013   | 18/12/2013 | SmPC, Annex II, Labelling and PL |                                             |
| II/0010   | Change in immediate packaging of the adjuvant. B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs                                                                                                                                                                                                                | 19/09/2013   | n/a        |                                  |                                             |
| IA/0012/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used of the AS                                                                                                                                                                                                   | 15/08/2013   | n/a        |                                  | in the manufacture                          |

<div style=\"page-break-after: always\"></div>

|             | - Administrative change - Change in the name address of a manufacturer or supplier of the starting material, reagent or intermediate used the manufacture of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |          | A.4 and/or AS, in     |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------|
| IAIN/0009/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 11/01/2013 | n/a        |          | the pharmacovigilance |
| II/0005/G   | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.z - Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                | 13/12/2012 | 18/12/2013 | Annex II |                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------|
| II/0007/G | This was an application for a group of variations. Update of sections 4.3 and 4.4 of the SmPC in order to add a contraindication and a warning for cases of known hypersensitivity to barium sulphate, which has been added to the list of trace residues. In addition, section 4.8 of the SmPC was updated concerning the duration of adverse events based on post-marketing surveillance data and concerning severe cases of thrombocytopenia based on a cumulative review data. The Package Leaflet is updated accordingly. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 15/11/2012 | 08/02/2013 | SmPC and PL | Please refer to the scientific discussion of the Assessment Report Aflunov-H-2094-II-0007-G-AR. |
| IAIN/0008 | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 28/09/2012 | n/a        |             |                                                                                                 |

<div style=\"page-break-after: always\"></div>

|           | MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006/G | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                | 20/06/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0001   | Change of virus used in manufacture from a A/VietNam/1194/2004 (H5N1) - like strain (NIBRG- 14) to a A/turkey/Turkey/1/05 (H5N1) - like strain (NIBRG-23). B.I.a.5.a - Changes to the AS of a seasonal, prepandemic or pandemic vaccine against human influenza - Replacement of the strain(s) in a seasonal, prepandemic or a pandemic vaccine against human influenza                                                                                                                                           | 15/03/2012 | 20/04/2012 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0003   | Update of the safety information in section 4.8 of the SmPC following CHMP request from FUM 004 based on data from study V87P1E1 on cross-reactivity after booster dose. In addition, the MAH took the opportunity to update sections 8 and 9 of the SmPC and Annex IIIA to include the Date of First Authorisation and the MA Numbers, and to make a minor editorial change in section 4.6. Furthermore the information on pediatric population in section 4.2 and 5.1 of the SmPC has been revised based on the | 15/12/2011 | 06/02/2012 | SmPC and Labelling     | Section 4.8 of the SmPC was updated to reflect data from Study V87P1E1, which showed 72% of solicited reactions in adults and 39% in elderly. These numbers are higher than those detected after the previous doses, indicating a tendency towards an increased reactogenicity after a booster dose. Furthermore, in the elderly the reported reactions increased with the third booster dose when compared with the second dose. |

<div style=\"page-break-after: always\"></div>

|           | SmPC guideline. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|
| IAIN/0004 | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 18/11/2011 | n/a |          |
| IA/0002/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.f - Changes to an existing pharmacovigilance system as described in the DDPS - Deletion of topics covered by written procedure(s) describing | 06/05/2011 | n/a | Annex II |

<div style=\"page-break-after: always\"></div>

| pharmacovigilance activities C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|